[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Renovorx Inc (RNXT)

Renovorx Inc (RNXT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 41,013
  • Shares Outstanding, K 45,099
  • Annual Sales, $ 1,120 K
  • Annual Income, $ -11,170 K
  • EBIT $ -13 M
  • EBITDA $ -13 M
  • 60-Month Beta 1.00
  • Price/Sales 39.72
  • Price/Cash Flow N/A
  • Price/Book 3.96
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.32
  • Most Recent Earnings $-0.08 on 05/14/26
  • Next Earnings Date 08/13/26
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.08
  • Number of Estimates 2
  • High Estimate $-0.07
  • Low Estimate $-0.08
  • Prior Year $-0.08
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.7700 +18.10%
on 05/19/26
0.9900 -8.14%
on 05/28/26
+0.0783 (+9.42%)
since 04/29/26
3-Month
0.7700 +18.10%
on 05/19/26
1.3000 -30.05%
on 03/26/26
+0.0264 (+2.99%)
since 02/27/26
52-Week
0.7006 +29.80%
on 11/14/25
1.4500 -37.28%
on 09/19/25
-0.3856 (-29.78%)
since 05/28/25

Most Recent Stories

More News
RenovoRx Announces FDA Orphan Drug Designation Granted: Oxaliplatin for the Treatment of Pancreatic Cancer

MOUNTAIN VIEW, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. ("RenovoRx" or "the Company") (Nasdaq: RNXT) , a life sciences company developing innovative targeted oncology therapies and...

RNXT : 0.9094 (-8.05%)
RenovoRx Announces Promising Pharmacokinetic Data Using the TAMP™ Platform Presented at the 2026 ASCO Annual Meeting

Sub-Study from Ongoing Phase III TIGeR-PaC Clinical Trial Supports TAMP for Targeted Intra-Arterial Delivery of Gemcitabine, Demonstrating Potential to Increase Local Drug Potency and Reduce Systemic Exposure...

RNXT : 0.9094 (-8.05%)
RenovoRx to Present at the Alliance Global Partners Virtual Annual Healthcare Company Showcase on May 20th

MOUNTAIN VIEW, Calif., May 19, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT) , a life sciences company developing innovative targeted oncology therapies...

RNXT : 0.9094 (-8.05%)
RenovoRx Reports Record First Quarter 2026: Increasing Revenue by 136% Quarter-over-Quarter

Q1 2026 Revenue of $563,000 Totals Over 50% of Full Year 2025 Total Revenue Active Commercial Cancer Center Customers Expand to 16 with Growing Sales Pipeline, Accelerating Adoption of the TAMP™...

RNXT : 0.9094 (-8.05%)
RenovoRx to Host First Quarter 2026 Financial Results and Business Highlights Conference Call on May 14th at 4:30 pm ET

MOUNTAIN VIEW, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT) , a life sciences company developing innovative targeted oncology therapies...

RNXT : 0.9094 (-8.05%)
RenovoRx Announces Pharmacokinetic and Pharmacodynamic Data Abstract Supporting the TAMP™ Therapy Platform Accepted for Presentation at the 2026 ASCO Annual Meeting

MOUNTAIN VIEW, Calif., April 23, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc . (“RenovoRx” or “the Company”) (Nasdaq: RNXT) , a life-sciences company developing innovative targeted oncology therapies...

RNXT : 0.9094 (-8.05%)
Clinical Data Supporting Targeted Chemotherapeutic Delivery via RenovoRx’s TAMP™ Therapy Platform Presented at 2026 SIR Annual Scientific Meeting

Data Shows TAMP to be a Promising Approach for Local Delivery of Gemcitabine with Reduced Systemic Toxicity in Patients Diagnosed with Locally Advanced Pancreatic Cancer  Metabolic Imaging, Used...

RNXT : 0.9094 (-8.05%)
RenovoRx Secures First Notice of Allowance for Japanese Patent Covering its RenovoCath® Device for Targeted, Local Drug-Delivery via the Vasa Vasorum

Patent Expands Protection for the Company’s RenovoCath Device, the Novel Dual-Occlusion Catheter-Based System  RenovoRx Currently Holds a Strong and Growing Global Intellectual Property Portfolio...

RNXT : 0.9094 (-8.05%)
RenovoRx Named to Fast Company’s Annual List of the World’s Most Innovative Companies of 2026

MOUNTAIN VIEW, Calif., April 01, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT) , a life-sciences company developing innovative targeted oncology...

RNXT : 0.9094 (-8.05%)
RenovoRx Reports Full Year 2025 Financial Results and Provides Business Update

RenovoCath ® Generates $1.1 Million in 2025 Revenue in First Full Year of Commercialization Phase III TIGeR-PaC Trial on Track for Enrollment Completion by the Middle of 2026, and Final Data...

RNXT : 0.9094 (-8.05%)

Business Summary

RenovoRx Inc. is a biopharmaceutical company. It developed a therapy platform targeting difficult-to-treat tumors. RenovoRx Inc. is headquartered in Silicon Valley, California.

See More

Key Turning Points

3rd Resistance Point 1.0452
2nd Resistance Point 1.0166
1st Resistance Point 0.9630
Last Price 0.9094
1st Support Level 0.8808
2nd Support Level 0.8522
3rd Support Level 0.7986

See More

52-Week High 1.4500
Fibonacci 61.8% 1.1637
Fibonacci 50% 1.0753
Fibonacci 38.2% 0.9869
Last Price 0.9094
52-Week Low 0.7006

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.